Advanced Enzyme Technologies Limited

Low capital efficiency: ROE 11.05% paired with PE 20.55 implies an earnings yield of ~5.4%—verify what earnings growth justifies this valuation multiple.

Revenue structure ambiguity: Quarterly figures show wide variation (₹95–203 Cr), with a consistent gap between two reported data sets per quarter—verify whether standalone/consolidated split explains divergence and what this implies for group stability.

Margin volatility: OPM ranges from 23% to 33% quarter-to-quarter across reported figures—verify whether driven by operational execution, product mix, or consolidation methodology.

Market underperformance: Stock returned –2.5% over one year despite regular dividends and trading ₹304.3 near the 52-week low of ₹255.3—verify whether this reflects sector headwinds or company-specific concerns.

Potential subsidiary contribution: Within-quarter revenue figures show consistent gaps of ₹70–90 Cr between data sets, with higher figures showing superior margins (26.86–32.55% vs 23.07–28.71%)—verify ownership structure and accretion opportunity.

Consistent cash generation: Quarterly dividends paid throughout 2024–2026 indicate operational cash flow—verify capital allocation between shareholder returns and growth capex.

Balance-sheet capacity: D/E ratio of 0.01 provides headroom for debt-funded growth or acquisitions—verify management's strategic priorities for deploying capital.

Margin base to scale: Operating margins sustained at 26–32% across cycles provide cushion for scaling—verify if this reflects pricing power, cost discipline, or product mix that can support growth.